Abstract
Sex differences in human muscle strength, size, and quality are well characterised, but their alteration with age is less clear. Here we report a novel and striking sexual dimorphism in arm muscle ageing in 478,438 UK Biobank participants aged 40–82 yr. While there was a modest sex difference in age-related strength decline, muscle mass loss was considerably more pronounced in males, both in absolute and percentage terms. We also introduce a novel measure of muscle quality, which showed substantially greater age-related decline in females. These trends held across independent analyses of separate cross-sectional and longitudinal participant groups, and persisted after accounting for systematic size differences between the sexes. Furthermore, sex differences were apparent irrespective of female menopause status or HRT usage history. Defining sarcopenia on the basis of muscle mass is therefore inappropriate, particularly for females. Our findings demonstrate that sex-specific criteria based on muscle function, not mass, should be used to diagnose sarcopenia, and prompt consideration of sex-specific interventions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Medical Research Council Scientist Programme Grant MR/N021231/1.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The North West Multi-centre Research Ethics Committee gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos